This is because a number of anti-TNF agents, including infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab, are widely used to treat inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis (64). The gene discussed is TNF; the disease is psoriatic arthritis.